Trial Profile
Effect of the Rivaroxaban and macitentan inducer St. John's Wort (SJW) on the pharmacokinetics of these drugs in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Macitentan (Primary) ; Rivaroxaban (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary thrombosis; Deep vein thrombosis; Embolism; Peripheral arterial disorders; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis; Venous thromboembolism
- Focus Pharmacokinetics
- 12 Sep 2018 New trial record
- 07 Sep 2018 Results published in the British Journal of Clinical Pharmacology